Heart failure: the commonest reason for hospital admission in Germany: medical and economic perspectives T Neumann, J Biermann, R Erbel, A Neumann, J Wasem, G Ertl, R Dietz Deutsches Ärzteblatt International 106 (16), 269, 2009 | 349 | 2009 |
Cost effectiveness of peginterferon α-2b plus ribavirin versus interferon α-2b plus ribavirin for initial treatment of chronic hepatitis C U Siebert, G Sroczynski, S Rossol, J Wasem, U Ravens-Sieberer, ... Gut 52 (3), 425-432, 2003 | 246 | 2003 |
Krankenhaus-Report 2013 J Klauber, M Geraedts, J Friedrich, J Wasem Schattauer Verlag, 2013 | 242* | 2013 |
Risk adjustment and risk selection on the sickness fund insurance market in five European countries WPMM Van de Ven, K Beck, F Buchner, D Chernichovsky, L Gardiol, ... Health policy 65 (1), 75-98, 2003 | 226 | 2003 |
Empirical standard costs for health economic evaluation in Germany--a proposal by the working group methods in health economic evaluation C Krauth, F Hessel, T Hansmeier, J Wasem, R Seitz, B Schweikert Gesundheitswesen (Bundesverband der Arzte des Offentlichen …, 2005 | 188 | 2005 |
Risk adjustment and risk selection in Europe: 6 years later WPMM Van de Ven, K Beck, C Van de Voorde, J Wasem, I Zmora Health policy 83 (2-3), 162-179, 2007 | 177 | 2007 |
German recommendations on health economic evaluation: third and updated version of the Hanover Consensus JM Graf von der Schulenburg, W Greiner, F Jost, N Klusen, M Kubin, ... Value in health 11 (4), 539-544, 2008 | 160 | 2008 |
Prognostic significance of FLT3 internal tandem duplication, nucleophosmin 1, and CEBPA gene mutations for acute myeloid leukemia patients with normal karyotype and younger … M Port, M Boettcher, F Thol, A Ganser, R Schlenk, J Wasem, A Neumann, ... Annals of hematology 93, 1279-1286, 2014 | 155 | 2014 |
Empirische Bewertungssätze in der gesundheitsökonomischen Evaluation-ein Vorschlag der AG Methoden der gesundheitsökonomischen Evaluation (AG MEG) C Krauth, F Hessel, T Hansmeier, J Wasem, R Seitz, B Schweikert Das Gesundheitswesen 67 (10), 736-746, 2005 | 152 | 2005 |
Zur Wirkung des Risikostrukturausgleichs in der gesetzlichen Krankenversicherung: eine Untersuchung im Auftrag des Bundesministeriums für Gesundheit K Jacobs, P Reschke, D Cassel, J Wasem (Schriftenreihe des Bundesministeriums für Gesundheit; 140), 2002 | 152 | 2002 |
Preconditions for efficiency and affordability in competitive healthcare markets: are they fulfilled in Belgium, Germany, Israel, the Netherlands and Switzerland? WPMM Van de Ven, K Beck, F Buchner, E Schokkaert, FTE Schut, ... Health policy 109 (3), 226-245, 2013 | 142 | 2013 |
Consumer price sensitivity and social health insurer choice in Germany and the Netherlands FT Schut, S Greß, J Wasem International journal of health care finance and economics 3, 117-138, 2003 | 138 | 2003 |
Deutsche Empfehlungen zur gesundheitsökonomischen Evaluation-dritte und aktualisierte Fassung des Hannoveraner Konsens JMG von der Schulenburg, W Greiner, F Jost, N Klusen, M Kubin, R Leidl, ... Gesundheitsökonomie & Qualitätsmanagement 12 (05), 285-290, 2007 | 133 | 2007 |
Impact of 4 different definitions used for the assessment of the prevalence of the Metabolic Syndrome in primary healthcare: The German Metabolic and Cardiovascular Risk … S Moebus, JU Hanisch, P Aidelsburger, P Bramlage, J Wasem, KH Jöckel Cardiovascular Diabetology 6, 1-10, 2007 | 132 | 2007 |
Methods for health economic evaluation of vaccines and immunization decision frameworks: a consensus framework from a European vaccine economics community B Ultsch, O Damm, P Beutels, J Bilcke, B Brüggenjürgen, A Gerber-Grote, ... Pharmacoeconomics 34, 227-244, 2016 | 125 | 2016 |
Free choice of sickness funds in regulated competition: evidence from Germany and the Netherlands S Greß, P Groenewegen, J Kerssens, B Braun, J Wasem Health policy 60 (3), 235-254, 2002 | 125 | 2002 |
Needs for further improvement: risk adjustment in the German health insurance system F Buchner, J Wasem Health Policy 65 (1), 21-35, 2003 | 110 | 2003 |
Dyslipidemia in primary care–prevalence, recognition, treatment and control: data from the German Metabolic and Cardiovascular Risk Project (GEMCAS) E Steinhagen-Thiessen, P Bramlage, C Lösch, H Hauner, H Schunkert, ... Cardiovascular Diabetology 7, 1-11, 2008 | 102 | 2008 |
Economic evaluation of treatment options in patients with Alzheimer’s disease: a systematic review of cost-effectiveness analyses L Pouryamout, J Dams, J Wasem, R Dodel, A Neumann Drugs 72, 789-802, 2012 | 101 | 2012 |
Treatment costs and indirect costs of cluster headache: a health economics analysis C Gaul, J Finken, J Biermann, S Mostardt, HC Diener, O Müller, J Wasem, ... Cephalalgia 31 (16), 1664-1672, 2011 | 100 | 2011 |